STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more

Physicians and experts in Prader-Willi syndrome have notified clinicians about patient deaths and severe side effects potentially linked to Vykat XR, a newly approved drug from Neurocrine Biosciences. Since FDA approval last year, seven patients prescribed the drug have died, according to the FDA's Adverse Event Monitoring System, and more than 100 serious adverse events—mostly hospitalizations for swelling, respiratory, and heart complications—have been reported.

In a separate legal escalation, Eli Lilly filed six lawsuits against U.S. companies it accuses of selling black-market versions of its still-experimental obesity drug retatrutide. The suits target compounding pharmacies, medical spas, and online sellers that marketed retatrutide despite its status in Phase 3 clinical trials for obesity, type 2 diabetes, and related conditions.